BACKGROUND: Although AJCC/TNM staging remains the gold standard for prognostic assessment of colon cancer, stage-specific outcomes vary. We therefore prospectively evaluated the prognostic role of immunoprofiling. METHODS: Our cohort included 35 patients from an ongoing prospective trial of ultrastaging for colon cancer. Specimens were analyzed for T cell markers (CD3, CD4, CD8, and FoxP3). The number of tumor-infiltrating lymphocytes was analyzed at the tumor's margin and center and correlated with AJCC/TNM stage, clinicopathologic variables, and disease-free survival. RESULTS: There was a significant inverse association between number of CD3(+) cells in the tumor center and tumor stage (P = 0.05). The tumor center/margin ratio of CD3(+) cells also showed an inverse but non-significant relationship with nodal involvement (P = 0.07). Body mass index was inversely associated with numbers of CD3(+)(P = 0.04) and CD8(+)(P = 0.02) cells. Longer disease-free survival was correlated with higher CD8+ counts (P = 0.07), lower CD4(+)/CD8(+) ratios (P = 0.008), and higher CD8(+)/FoxP3(+) ratios (P = 0.02). CONCLUSIONS: This is the first prospective validation of immunoprofiling in patients whose colon cancer is staged with strict surgical and pathology quality measures. The apparent correlation between immunophenotypic response and clinical outcome warrants evaluation in a larger prospective trial.
RCT Entities:
BACKGROUND: Although AJCC/TNM staging remains the gold standard for prognostic assessment of colon cancer, stage-specific outcomes vary. We therefore prospectively evaluated the prognostic role of immunoprofiling. METHODS: Our cohort included 35 patients from an ongoing prospective trial of ultrastaging for colon cancer. Specimens were analyzed for T cell markers (CD3, CD4, CD8, and FoxP3). The number of tumor-infiltrating lymphocytes was analyzed at the tumor's margin and center and correlated with AJCC/TNM stage, clinicopathologic variables, and disease-free survival. RESULTS: There was a significant inverse association between number of CD3(+) cells in the tumor center and tumor stage (P = 0.05). The tumor center/margin ratio of CD3(+) cells also showed an inverse but non-significant relationship with nodal involvement (P = 0.07). Body mass index was inversely associated with numbers of CD3(+)(P = 0.04) and CD8(+)(P = 0.02) cells. Longer disease-free survival was correlated with higher CD8+ counts (P = 0.07), lower CD4(+)/CD8(+) ratios (P = 0.008), and higher CD8(+)/FoxP3(+) ratios (P = 0.02). CONCLUSIONS: This is the first prospective validation of immunoprofiling in patients whose colon cancer is staged with strict surgical and pathology quality measures. The apparent correlation between immunophenotypic response and clinical outcome warrants evaluation in a larger prospective trial.
Authors: Anton Bilchik; Aviram Nissan; Zev Wainberg; Perry Shen; Martin McCarter; Mladjan Protic; Robin Howard; David Elashoff; Josh Tyler; George E Peoples; Alexander Stojadinovic Journal: Ann Surg Date: 2010-09 Impact factor: 12.969
Authors: Daniel J Sargent; Silvia Marsoni; Genevieve Monges; Stephen N Thibodeau; Roberto Labianca; Stanley R Hamilton; Amy J French; Brian Kabat; Nathan R Foster; Valter Torri; Christine Ribic; Axel Grothey; Malcolm Moore; Alberto Zaniboni; Jean-Francois Seitz; Frank Sinicrope; Steven Gallinger Journal: J Clin Oncol Date: 2010-05-24 Impact factor: 44.544
Authors: Anton J Bilchik; Dave S B Hoon; Sukamal Saha; Roderick R Turner; David Wiese; Maggie DiNome; Kazuo Koyanagi; Martin McCarter; Perry Shen; Douglas Iddings; Steven L Chen; Maria Gonzalez; David Elashoff; Donald L Morton Journal: Ann Surg Date: 2007-10 Impact factor: 12.969
Authors: Richard Gray; Jennifer Barnwell; Christopher McConkey; Robert K Hills; Norman S Williams; David J Kerr Journal: Lancet Date: 2007-12-15 Impact factor: 79.321
Authors: Mary Garland-Kledzik; Abhineet Uppal; Yalda B Naeini; Stacey Stern; Richard Erali; Anthony J Scholer; Adam M Khader; Juan A Santamaria-Barria; Kathleen Cummins-Perry; Yi Zhou; Konstantinos I Votanopoulos; Perry Shen; Edward A Levine; Anton J Bilchik Journal: J Gastrointest Surg Date: 2020-12-02 Impact factor: 3.452
Authors: Juliana Noguti; Alfred A Chan; Bradley Bandera; Colin J Brislawn; Mladjan Protic; Myung S Sim; Janet K Jansson; Anton J Bilchik; Delphine J Lee Journal: Oncotarget Date: 2018-05-04
Authors: Ann C Eriksen; Flemming B Sørensen; Jan Lindebjerg; Henrik Hager; René dePont Christensen; Sanne Kjær-Frifeldt; Torben F Hansen Journal: Transl Oncol Date: 2018-06-22 Impact factor: 4.243
Authors: Faraz Bishehsari; Phillip A Engen; Robin M Voigt; Garth Swanson; Maliha Shaikh; Sherry Wilber; Ankur Naqib; Stefan J Green; Brandon Shetuni; Christopher B Forsyth; Abdulrahman Saadalla; Abu Osman; Bruce R Hamaker; Ali Keshavarzian; Khashayarsha Khazaie Journal: Cell Mol Gastroenterol Hepatol Date: 2019-11-02